Incyte Corporation (INCY) Stock

Incyte Corporation (INCY) is a Technology stock trading at $98.27 (as of 2026-06-18), with a market capitalization of $19.33B and a trailing P/E of 13.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapies in the United States and internationally. Its marketed products include JAKAFI, PEMAZYRE, and ICLUSIG, and its clinical-stage portfolio includes ruxolitinib, itacitinib, pemigatinib, Parsaclisib, and retifanlimab for various hematologic and solid-tumor indications.

Valuation — source: SEC EDGAR (first-party)
Price$98.27
Market Cap$19.33B
P/E Ratio13.7
EV / EBITDA9.3
Price / Book3.44
Price / Sales3.61
DCF Value (model)$194.79
DCF Upside vs Price98.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$5.14B
Net Margin25.0%
Return on Equity25.5%
Current Ratio3.68
Revenue Growth (YoY)21.2%
EPS Growth (YoY)4018.8%
Financial Health — source: SEC EDGAR
Altman Z-Score8.66 (safe)
Valuation vs Sector & Industry
Stock P/E13.7
Sector P/E (Technology)32.6
Industry P/E (Business Services)27.1
vs Sector-58.1%
vs Industry-49.5%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBAKER BROS. ADVISORS LP ($2.89B)
Institutional Holders Tracked10
Congressional Trades (recent)3
Company
SectorTechnology
IndustryBusiness Services
CEOWilliam J. Meury
Employees2,617
CountryUS
IPO Date1993-11-04

Related Companies (Business model: Big Pharma / Branded Drugs; 8 closest by market cap; US-domiciled)

  • Amgen Inc. (AMGN)
  • Gilead Sciences, Inc. (GILD)
  • Pfizer Inc. (PFE)
  • Bristol-Myers Squibb Company (BMY)
  • Regeneron Pharmaceuticals, Inc. (REGN)
  • Biogen Inc. (BIIB)
  • Neurocrine Biosciences, Inc. (NBIX)
  • Moderna, Inc. (MRNA)
INCY earnings history · INCY institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.